160 related articles for article (PubMed ID: 35689144)
1. Changes in Companion Diagnostic Labelling: Implementation of FDA's April 2020 Guidance for Industry for In Vitro CDx Labeling for Specific Oncology Therapeutic Groups.
Cooper L; Chen J
Ther Innov Regul Sci; 2022 Sep; 56(5):689-697. PubMed ID: 35689144
[TBL] [Abstract][Full Text] [Related]
2. Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?
Ou SH; Soo RA; Kubo A; Kawaguchi T; Ahn MJ
Front Oncol; 2014; 4():58. PubMed ID: 24744988
[TBL] [Abstract][Full Text] [Related]
3. Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan.
Tazawa Y
Breast Cancer; 2016 Jan; 23(1):19-23. PubMed ID: 25605056
[TBL] [Abstract][Full Text] [Related]
4. Approval gap of pharmacogenomic biomarkers and in vitro companion diagnostics between the United States and Japan.
Shimazawa R; Ikeda M
J Clin Pharm Ther; 2014 Apr; 39(2):210-4. PubMed ID: 24405254
[TBL] [Abstract][Full Text] [Related]
5. FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring
Odogwu L; Mathieu L; Blumenthal G; Larkins E; Goldberg KB; Griffin N; Bijwaard K; Lee EY; Philip R; Jiang X; Rodriguez L; McKee AE; Keegan P; Pazdur R
Oncologist; 2018 Jun; 23(6):740-745. PubMed ID: 29438093
[TBL] [Abstract][Full Text] [Related]
6. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
Basile EM; Tolomeo D; Gluck E
Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
[TBL] [Abstract][Full Text] [Related]
7. Companion and complementary diagnostics for infectious diseases.
Dailey PJ; Elbeik T; Holodniy M
Expert Rev Mol Diagn; 2020 Jun; 20(6):619-636. PubMed ID: 32031431
[TBL] [Abstract][Full Text] [Related]
8. Incremental Revisions across the Life Span of Ophthalmic Devices after Initial Food and Drug Administration Premarket Approval, 1979-2015.
Gopal AD; Rathi VK; Teng CC; Del Priore L; Ross JS
Ophthalmology; 2017 Aug; 124(8):1237-1246. PubMed ID: 28501378
[TBL] [Abstract][Full Text] [Related]
9. Missing Companion Diagnostic for US Food and Drug Administration-Approved Hematological and Oncological Drugs.
Jørgensen JT
JCO Precis Oncol; 2022 Jun; 6():e2200100. PubMed ID: 35709402
[TBL] [Abstract][Full Text] [Related]
10. A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012-2016).
Gnanasakthy A; Barrett A; Evans E; D'Alessio D; Romano CD
Value Health; 2019 Feb; 22(2):203-209. PubMed ID: 30711065
[TBL] [Abstract][Full Text] [Related]
11. Off-label use of medical products in radiation therapy: summary of the report of AAPM Task Group No. 121.
Thomadsen BR; Heaton HT; Jani SK; Masten JP; Napolitano ME; Ouhib Z; Reft CS; Rivard MJ; Robin TT; Subramanian M; Suleiman OH
Med Phys; 2010 May; 37(5):2300-11. PubMed ID: 20527564
[TBL] [Abstract][Full Text] [Related]
12. The FDA Oncology Center of Excellence and precision medicine.
Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
[TBL] [Abstract][Full Text] [Related]
13. BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy.
Wiesweg M; Preuß C; Roeper J; Metzenmacher M; Eberhardt W; Stropiep U; Wedeken K; Reis H; Herold T; Darwiche K; Aigner C; Stuschke M; Schildhaus HU; Schmid KW; Falk M; Heukamp L; Tiemann M; Griesinger F; Schuler M
Eur J Cancer; 2021 May; 149():211-221. PubMed ID: 33872981
[TBL] [Abstract][Full Text] [Related]
14. Examination of the relationship between oncology drug labeling revision frequency and FDA product categorization.
Berlin RJ
Am J Public Health; 2009 Sep; 99(9):1693-8. PubMed ID: 19372515
[TBL] [Abstract][Full Text] [Related]
15. Twenty-five years with companion diagnostics.
Jørgensen JT
Chin Clin Oncol; 2023 Dec; 12(6):65. PubMed ID: 37953243
[TBL] [Abstract][Full Text] [Related]
16. Oncology drug-companion diagnostic combinations.
Jørgensen JT
Cancer Treat Res Commun; 2021; 29():100492. PubMed ID: 34844911
[TBL] [Abstract][Full Text] [Related]
17. Editorial: Global Regulatory Initiatives Deliver Accelerated Approval of the First Bispecific Therapeutic Monoclonal Antibody for Advanced Non-Small Cell Lung Cancer (NSCLC).
Parums DV
Med Sci Monit; 2021 Sep; 27():e934854. PubMed ID: 34565792
[TBL] [Abstract][Full Text] [Related]
18. BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall.
Leonetti A; Facchinetti F; Rossi G; Minari R; Conti A; Friboulet L; Tiseo M; Planchard D
Cancer Treat Rev; 2018 May; 66():82-94. PubMed ID: 29729495
[TBL] [Abstract][Full Text] [Related]
19. How do Orthopaedic Devices Change After Their Initial FDA Premarket Approval?
Samuel AM; Rathi VK; Grauer JN; Ross JS
Clin Orthop Relat Res; 2016 Apr; 474(4):1053-68. PubMed ID: 26584802
[TBL] [Abstract][Full Text] [Related]
20. Comparative evaluation of the new FDA approved THxID™-BRAF test with High Resolution Melting and Sanger sequencing.
Marchant J; Mange A; Larrieux M; Costes V; Solassol J
BMC Cancer; 2014 Jul; 14():519. PubMed ID: 25037456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
